These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 34731462)

  • 1. Direct Oral Anticoagulants Combined with Antiplatelet Therapy in the Treatment of Coronary Heart Disease: An Updated Meta-analysis.
    Liu L; Lei H; Hu J; Tang Y; Xu D
    Drugs; 2021 Nov; 81(17):2003-2016. PubMed ID: 34731462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis.
    Oldgren J; Wallentin L; Alexander JH; James S; Jönelid B; Steg G; Sundström J
    Eur Heart J; 2013 Jun; 34(22):1670-80. PubMed ID: 23470494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Antiplatelet Therapy Plus Xa Factor Inhibitors in Patients with Coronary Heart Disease: A Meta-Analysis.
    Chen H; Chen C; Fang J; Wang R; Nie W; Yuan Q
    Med Sci Monit; 2019 Jul; 25():5473-5481. PubMed ID: 31335859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of Stroke vs. Intracerebral Hemorrhage in Patients with Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Comparing Dual vs. Triple Antithrombotic Therapy.
    Desai A; Escamilla-Ocanas C; Dilip D; Saber H; Damani R
    J Stroke Cerebrovasc Dis; 2021 Apr; 30(4):105654. PubMed ID: 33578352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination anticoagulant or P2Y12 inhibitor with low-dose aspirin versus low-dose aspirin alone in patients at risk or with documented coronary and/or peripheral artery disease.
    Coleman CI; Kharat AA; Bookhart B; Baker WL
    Curr Med Res Opin; 2022 Jan; 38(1):27-34. PubMed ID: 34641745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stroke of antiplatelet and anticoagulant therapy in patients with coronary artery disease: a meta-analysis of randomized controlled trials.
    Shao QY; Wang ZJ; Ma XT; Lin XZ; Pan L; Zhou YJ
    BMC Cardiovasc Disord; 2021 Dec; 21(1):574. PubMed ID: 34852763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
    Connolly SJ; Eikelboom JW; Bosch J; Dagenais G; Dyal L; Lanas F; Metsarinne K; O'Donnell M; Dans AL; Ha JW; Parkhomenko AN; Avezum AA; Lonn E; Lisheng L; Torp-Pedersen C; Widimsky P; Maggioni AP; Felix C; Keltai K; Hori M; Yusoff K; Guzik TJ; Bhatt DL; Branch KRH; Cook Bruns N; Berkowitz SD; Anand SS; Varigos JD; Fox KAA; Yusuf S;
    Lancet; 2018 Jan; 391(10117):205-218. PubMed ID: 29132879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of dual-pathway inhibition in patients with cardiovascular disease: a meta-analysis of 49 802 patients from 7 randomized trials.
    Galli M; Capodanno D; Benenati S; D'Amario D; Crea F; Andreotti F; Angiolillo DJ
    Eur Heart J Cardiovasc Pharmacother; 2022 Aug; 8(5):519-528. PubMed ID: 34146091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    ; Bittl JA; Baber U; Bradley SM; Wijeysundera DN
    Circulation; 2016 Sep; 134(10):e156-78. PubMed ID: 27026019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombotic therapy in coronary artery disease patients with atrial fibrillation.
    Wei L; Su E; Liu W; Xing W; Liu X; Zhang Y; Wang S; Cheng Q; Qi D; Gao C
    BMC Cardiovasc Disord; 2020 Jul; 20(1):323. PubMed ID: 32631244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ticagrelor as compared to conventional antiplatelet agents in coronary artery disease: A comprehensive meta-analysis of 15 randomized trials.
    Verdoia M; Savonitto S; Dudek D; Kedhi E; De Luca G
    Vascul Pharmacol; 2021 Apr; 137():106828. PubMed ID: 33385541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct Xa inhibitors in addition to antiplatelet therapy in acute coronary syndrome: meta-analysis of randomized trials.
    Villablanca PA; Holmes D; Mohananey D; Briceno DF; Núñez Gil IJ; Kargoli F; Gupta T; Kizer JR; Bortnick AE; Wiley J; Menegus MA; Pyo R; García M; Ramakrishna H; Mookadam F
    Coron Artery Dis; 2017 Aug; 28(5):395-405. PubMed ID: 28328784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genotype-Guided Antiplatelet Therapy Versus Standard Therapy for Patients with Coronary Artery Disease: An Updated Systematic Review and Meta-Analysis.
    Tang B; Wang X; Wang X; Liu L; Ma Z
    J Pharm Pharm Sci; 2022; 25():9-23. PubMed ID: 34995471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of DOACs in patients with peripheral arterial disease: A systematic review and meta-analysis.
    Zhang YS; Chen JH; Mei T; Li S; Lu YM
    Vascular; 2021 Dec; 29(6):846-855. PubMed ID: 33504278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Bittl JA; Baber U; Bradley SM; Wijeysundera DN
    J Am Coll Cardiol; 2016 Sep; 68(10):1116-39. PubMed ID: 27036919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct Oral Anticoagulants in Addition to Antiplatelet Therapy for Secondary Prevention After Acute Coronary Syndromes: A Systematic Review and Meta-analysis.
    Chiarito M; Cao D; Cannata F; Godino C; Lodigiani C; Ferrante G; Lopes RD; Alexander JH; Reimers B; Condorelli G; Stefanini GG
    JAMA Cardiol; 2018 Mar; 3(3):234-241. PubMed ID: 29417147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of the Use of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Ischemic Heart Disease: A Meta-Analysis of Phase III Randomized Trials.
    Fu L; Zhu W; Huang L; Hu J; Ma J; Lip GYH; Hong K
    Am J Cardiovasc Drugs; 2019 Feb; 19(1):37-47. PubMed ID: 30182350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events.
    Lemesle G; Ducrocq G; Elbez Y; Van Belle E; Goto S; Cannon CP; Bauters C; Bhatt DL; Steg PG;
    Clin Cardiol; 2017 Oct; 40(10):932-939. PubMed ID: 28692742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial.
    Korjian S; Braunwald E; Daaboul Y; Verheugt F; Bode C; Tendera M; Jain P; Plotnikov A; Burton P; Gibson CM
    Eur Heart J Acute Cardiovasc Care; 2019 Mar; 8(2):186-193. PubMed ID: 29249166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial.
    Mehra MR; Vaduganathan M; Fu M; Ferreira JP; Anker SD; Cleland JGF; Lam CSP; van Veldhuisen DJ; Byra WM; Spiro TE; Deng H; Zannad F; Greenberg B
    Eur Heart J; 2019 Nov; 40(44):3593-3602. PubMed ID: 31461239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.